A pending federal move to reschedule marijuana, new testing requirements for fentanyl, and a patchwork of conflicting state laws are all converging in 2026, and each one touches addiction treatment in a different way.
For people currently in treatment, returning to work after treatment, or weighing whether to seek help at all, workplace drug testing rules can shape decisions about medication, disclosure, and even whether to come forward for care.
Marijuana Rescheduling Could Change Disability Protections
In December 2025, President Trump signed an executive order directing the U.S. Department of Justice to move marijuana from a Schedule I to a Schedule III drug under the federal Controlled Substances Act.
That change, if finalized in 2026, would not make marijuana legal at the federal level, but it would formally recognize the drug as having an accepted medical use.
That distinction matters for anyone using medical marijuana for a diagnosed condition. Schedule III drugs are eligible for disability accommodation consideration under the Americans with Disabilities Act, a protection that has been largely unavailable to medical marijuana cardholders because of marijuana’s current Schedule I status.
Employees with qualifying conditions such as chronic pain or PTSD could see new avenues for accommodation, though state disability and marijuana laws will continue to vary widely.
Employers still retain the right to discipline or fire employees who are impaired on the job, and a positive drug test alone does not prove impairment.
That gap between testing and impairment has long complicated addiction treatment conversations, since a positive result can trigger consequences regardless of whether a person’s use is medical, recreational, or a documented part of an addiction treatment plan.
Fentanyl and Ketamine Testing Are Expanding
Employers are increasingly testing for substances beyond the standard five-panel screen, which checks for amphetamines, cocaine, marijuana, opioids, and PCP.
The U.S. Department of Health and Human Services added fentanyl and norfentanyl to its testing guidelines for federal employees in safety-sensitive roles, with enforcement starting in mid-2025.
The Department of Transportation has proposed a similar expansion for private-sector transportation workers in trucking, aviation, rail, and other safety-sensitive industries, with a final rule expected in early 2026.
This expansion reflects a workplace reality tied directly to the broader opioid crisis: employers are managing not just traditional opioid misuse but a growing presence of fentanyl and, in some cases, ketamine among employees.
For people receiving medication-assisted treatment for opioid use disorder, expanded testing panels raise new questions about how prescribed medications like buprenorphine are documented and explained to employers.
Saliva Testing Could Streamline the Process
A new saliva-based testing protocol, established by federal health guidelines, could eventually replace some urine testing.
Saliva tests can be administered on-site under direct observation without the privacy logistics urine collection requires, which employers see as a practical advantage.
That said, federally regulated employers cannot adopt saliva testing until laboratories are certified to perform it, so urine testing remains the standard for now.
What This Means for Treatment Seekers
Anyone currently in addiction treatment, or considering it, should expect workplace drug policy to keep shifting through 2026.
Employees using MAT medications should know their rights vary significantly by state, and documentation from a treatment provider can matter if a workplace test flags a prescribed medication.
People in recovery who use medical marijuana under a state program should also confirm how their state’s disability and employment protections interact with their specific job duties, since federal rescheduling would not override safety-sensitive job restrictions.
Exploring Treatment Options
These policy changes are a reminder that addiction treatment decisions often intersect with employment concerns, from disclosure worries to insurance coverage tied to a job.
Anyone navigating a new diagnosis, a return to work after treatment, or a workplace drug test result has options worth exploring:
- Understanding how medication-assisted treatment, including buprenorphine and methadone, is documented for workplace purposes
- Comparing rehab centers that offer confidential, flexible scheduling for working adults
- Verifying insurance coverage for addiction treatment before starting a program
- Learning how state marijuana and disability laws apply to a specific job or industry
Rehab.com’s directory connects people with verified treatment centers nationwide. Call
800-985-8516
( 
Sponsored Helpline )
to speak with a treatment professional about options that fit your situation.
